Trial Profile
Prospective Observational Trial to Evaluate the Efficacy of the Combination of Osimertinib and Aspirin in Patients With Disease Progression to 3st Generation Epidermal Growth Factor Receptor-tyrosine Kinase InhibitorEGFR-TKI Osimertinib
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Jan 2023
Price :
$35
*
At a glance
- Drugs Aspirin (Primary) ; Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 22 Jul 2020 Planned initiation date changed from 1 Dec 2019 to 1 Aug 2020.
- 29 Nov 2019 Planned number of patients changed from 200 to 100.
- 29 Nov 2019 Planned End Date changed from 30 Jun 2022 to 31 Dec 2022.